Clinical Trials
12 trialsNCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT05325866 2026-02-04
FORTITUDE-301
Amgen
Phase 1/2 Completed
NCT07341737 2026-01-15
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Phase 1/2 Not yet recruiting
NCT04557449 2025-10-01
CDK4i
Pfizer
Phase 2 Active not recruiting
NCT06299163 2025-07-23
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Phase 1 Terminated
NCT04682431 2024-03-22
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT04691375 2024-03-22
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT05498597 2023-10-19
AMT-151 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
Phase 1 Unknown
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT00101972 2022-02-22
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
Phase 1 Completed
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT02485119 2018-06-04
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
Bayer
Phase 1 Completed